SCHEMBL395231

SCHEMBL395231

CC1=C[CH]c2ccccc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.47
KMT2A Q03164 7/20 0.47
CDC25B P30305 7/20 0.47
MAPT P10636 6/20 0.47
CDC25A P30304 6/20 0.47
LMNA P02545 4/20 0.47
IDO1 P14902 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 4/20 0.47
BLM P54132 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPK1 P28482 3/20 0.47
TP53 P04637 3/20 0.47
CYP1A2 P05177 3/20 0.47
CYP3A4 P08684 3/20 0.47
PKM P14618 2/20 0.47
PLIN1 O60240 2/20 0.47
MAOA P21397 2/20 0.47
PLIN5 Q00G26 2/20 0.47
ABHD5 Q8WTS1 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216842 0.81 LMNA (0.36) MEN1KMT2ACDC25BMAPTCDC25A
SCHEMBL27389227 0.79 LMNA (0.35) MEN1KMT2ACDC25BMAPTCDC25A
SCHEMBL678100 0.77 MAPT (0.61) MEN1KMT2ACDC25BMAPTCDC25A
SCHEMBL28865587 0.74 LMNA (0.31) LMNAACHE
SCHEMBL28249231 0.74 LMNA (0.31) LMNAACHE
SCHEMBL27499719 0.74 LMNA (0.31) LMNAACHE
SCHEMBL30715504 0.71 CDC25B (0.57) MEN1KMT2ACDC25BMAPTCDC25A
SCHEMBL8773107 0.71 CDC25B (0.57) MEN1KMT2ACDC25BMAPTCDC25A
Formic Acid SCHEMBL31606783 0.69 MAPT (0.52) MEN1KMT2ACDC25BMAPTCDC25A
SCHEMBL10885342 0.68 CDC25B (0.44) MEN1KMT2ACDC25BMAPTCDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101649-B2 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors NEUROSEARCH A/S (DK) 2012-01-24 US disclosed
US-20100280092-A1 N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2010-11-04 US disclosed
EP-2212285-A1 N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NeuroSearch A/S (DK) 2010-08-04 EP disclosed
WO-2009065854-A1 N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280092-A1 N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS CHRNA3, CHRNA6, CHRNA2 MEN1 4049/4885KMT2A 1615/4885CDC25B 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.